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Although DNA helicases play important  roles  in  the 
processing of DNA, little  is  known about the effects of 
DNA-interacting  ligands on these helicases. Therefore, 
the effects of a wide variety of DNA-binding ligands 
on the  unwinding  and ATPase reactions catalyzed by 
Escherichia  coli DNA helicase I1 were examined. DNA 
minor groove binders  and simple DNA intercalators 
did not inhibit helicase 11. However, DNA intercala- 
tors, such as mitoxantrone and nogalamycin, which 
position functionalities in the major groove upon bind- 
ing duplex DNA, were potent inhibitors of helicase 11. 
To determine  the mechanism by which mitoxantrone 
inhibited helicase 11, the  unwinding  and DNA-depend- 
ent ATPase activities of helicase I1 were measured 
using a spectrum of double- and single-stranded DNA 
substrates. Using either a 71-base  pair (bp) M13mp7 
partially duplexed DNA substrate or a 245-bp  blunt- 
ended, fully duplexed DNA substrate,  the  apparent Ki 
value  for inhibition by mitoxantrone of both the un- 
winding and ATPase reactions was -1 FM for both 
substrates, suggesting that  the mechanism of inhibition 
of helicase I1 by mitoxantrone is the same for both 
substrates  and  requires  the presence of double- 
stranded  structure. To strengthen  this conclusion, the 
ability of mitoxantrone  to  inhibit  the DNA-dependent 
ATPase  activity of helicase I1 was  determined using 
two  single-stranded  substrates, poly(dT) and  the 245- 
bp  substrate  after  heat  denaturation. Using either sub- 
strate, mitoxantrone  inhibited the ATPase activity of 
helicase I1 far less effectively. Thus, these results  in- 
dicate  that  the  intercalation of mitoxantrone  into dou- 
ble-stranded DNA, with accompanying placement of 
functionalities  in  the major groove, generates  a com- 
plex that impedes helicase 11, resulting in both inhibi- 
tion of ATP hydrolysis  and  unwinding  activity. Fur- 
thermore, we report  here  that DNA-binding ligands 
inhibit  the  unwinding  activity of helicases I and IV and 
Rep  protein  from E. coli, demonstrating that  the inhi- 
bition observed for helicase I1 is not unique to this 
enzyme. 
Ligands that bind DNA have generated great interest in 
the last 30 years due in part  to  their antibiotic  and  antitumor 
properties (1, 2). These drugs can be characterized by their 
mechanisms of physical interaction with DNA.  DNA inter- 
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calators  are generally planar polycyclic compounds that bind 
to double-stranded DNA (dsDNA)’ by inserting between base 
pairs, resulting in the partial unwinding of dsDNA around 
the intercalation  site (3-5). Additional structural features of 
intercalators may include a cationically charged functionality 
on the chromophore and  structures  that reside in the major 
or minor groove of dsDNA. In some cases, functionalities 
reside in both grooves of DNA. Other  antibiotics have  been 
shown to bind to  the minor groove of dsDNA. These minor 
groove binders are highly AT base pair (bp)-specific and 
require at least 3 consecutive AT bp  to bind (6, 7). 
Many DNA-binding compounds have been shown to inhibit 
DNA and RNA metabolism by binding to  the nucleic acid 
and disrupting the enzymatic machinery that interacts with 
it. For example, daunomycin has been shown to inhibit DNA- 
directed RNA synthesis by inhibiting Escherichia coli RNA 
polymerase i n  vitro (8). DNA topoisomerases, which are  in- 
volved in all facets of DNA and RNA metabolism (9-12), can 
also be inhibited by a number of these DNA-binding ligands. 
The mechanism by which DNA intercalators inhibit topoi- 
somerases has been intensively studied. Effective intercala- 
tors  trap  the cleaved intermediate in the reaction, generating 
a  ternary complex containing  a covalent topoisomerase-DNA 
complex bound with the intercalator (13). This  appears to be 
a common mechanism of inhibition for type I1 topoisomerases 
(14). The precise mechanism by which the generation of the 
cleavable complex causes cell death is unknown, but it appears 
to be the primary requirement for cytotoxicity of these com- 
pounds (15). 
Until now, no work has been performed to consider the 
effects of these DNA-interacting ligands on the DNA heli- 
cases.  DNA helicases are DNA-dependent nucleoside 5’-tri- 
phosphatases that catalyze the unwinding of dsDNA (16). 
This important class of enzymes functions in DNA replica- 
tion,  repair,  and recombination. In E. coli, at least 10 different 
helicases have been described. Helicases have also been de- 
scribed in bacteriophage, viral, and eukaryotic systems (17). 
E. coli helicase I1 (uurD gene product) was chosen as  the focus 
of the studies reported here because it is one of the most 
extensively characterized helicases at present. The enzyme is 
a DNA-dependent ATPase that translocates unidirectionally 
on single-stranded DNA (ssDNA) by a processive mechanism 
(18). The unwinding of dsDNA has been shown to occur in 
the 3‘ to 5‘ direction with respect to  the  strand on  which the 
enzyme initially binds. At  low concentrations of enzyme, 
unwinding occurs by a  concentration-dependent mechanism 
The abbreviations used are: dsDNA, double-stranded DNA; bp, 
base pairk); ssDNA, single-stranded DNA; DAPI, 4,6-diamidino-2- 
phenylindole; m-AMSA, 4’-(9-acridinylamino)methanesulfon-m-an- 
isidide. 
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in a reaction that requires a ssDNA-binding site for initial 
binding of the protein (19). At higher helicase I1 concentra- 
tions, unwinding of duplex DNA can be measured using 
helicase substrates lacking ssDNA (20). Genetic and biochem- 
ical studies have revealed roles for helicase I1 in UvrABC 
excision repair and methyl-directed mismatch repair (17,21). 
The enzyme  may have additional roles in DNA replication, 
recombination, and  transposon excision based on known phe- 
notypes of uvrD mutants (17, 21). 
Here we report studies designed to determine the effect of 
various DNA-binding compounds on the helicase and ATPase 
activities of helicase 11. The most potent  inhibitors of helicase 
I1 were intercalators that position functionalities in  the major 
groove of dsDNA. In addition, an analysis of the effect of 
several of these drugs on helicases I  and IV and Rep protein 
from E. coli demonstrates that  the inhibition observed for 
helicase I1 is not unique to  this enzyme. Furthermore, the 
spectrum of sensitivities to  the compounds is enzyme-specific. 
The inhibition of helicases by these ligands may  be important 
in explaining some of the properties exhibited by these com- 
pounds in vivo. 
EXPERIMENTAL PROCEDURES 
Materials 
DNA and Nucleotides-Bacteriophage  M13mp7 replicative form I 
DNA and ssDNA were prepared as described (22). All unlabeled 
nucleotides were  from  U. S. Biochemical Corp. [a-32P]dCTP  and [y- 
"PIATP were  from ICN Radiochemicals or Amersham Corp. 
Poly(dT) was purchased from P-L Biochemicals. Concentrations of 
DNA and nucleotides were determined by UV spectrophotometry 
using published extinction coefficients. 
Enzymes-Restriction endonucleases, DNA polymerase I (large 
fragment), bacteriophage T4 polynucleotide kinase, and bacterial 
alkaline phosphatase were purchased from New England BioLabs, 
Inc., or U. S. Biochemical Corp. The reaction conditions used were 
those suggested by the supplier. Proteinase K was purchased from 
Boehringer Mannheim. E. coli helicase 11, Rep protein, and helicases 
I and IV  were purified as previously described (18, 23-25). 
DNA-binding Ligands-The compounds used in this study were 
the generous gift of Glaxo Inc. The compounds were dissolved into 
dimethyl sulfoxide at 2 mM and stored at 4 "C in the dark. Concen- 
trations were checked by spectrophotometry using published extinc- 
tion coefficients. 
Methods 
Helicase Substrate Preparation-The 71-bp M13mp7 partially  du- 
plexed helicase substrate was constructed as described (19). The 245- 
bp blunt-ended helicase substrate was constructed by digesting 33 pg 
of  M13mp7 replicative form I DNA to completion with HueIII. After 
digestion, bacterial alkaline phosphatase was added to remove the 5'- 
phosphoryl groups. The reaction was terminated by the addition of 
100 pg/ml proteinase K and 0.1% sodium dodecyl sulfate and incu- 
bated at 37 "C for 30 min. The DNA  was subsequently applied to a 
nondenaturing polyacrylamide gel to resolve the products. The 245- 
bp DNA fragment was electroeluted, precipitated with isopropyl 
alcohol, and suspended in polynucleotide kinase buffer. The resus- 
pended DNA  was labeled using phage T4 polynucleotide kinase and 
[y-"PIATP as described (26). To ensure that all 5'-ends were phos- 
phorylated, the reaction was chased with 100 PM ATP. After phenol 
extraction, the ["PIDNA was separated from unincorporated ATP 
by filtration through an agarose A-5m column (1.5 ml) equilibrated 
with 10 mM Tris-HC1 (pH 7.5), 1 mM EDTA, and 100 mM NaCl. The 
void volume containing the labeled DNA was collected and used 
directly as helicase substrate. 
Helicase  Assays-The helicase assay measures either the displace- 
ment of a labeled  DNA fragment from a  partial duplex DNA  molecule 
or  the denaturation of a fully duplex [32P]DNA fragment by native 
polyacrylamide gel electrophoresis. The reaction mixture (20 pl) 
contained 40 mM Tris-HC1 (pH 7.5), 4 mM MgC12, 1 mM dithiothre- 
itol, 50 pg/ml bovine serum albumin, 5% dimethyl sulfoxide, 10 mM 
NaCl, 2 or 4 mM rATP, [3'P]DNA substrate, and  the indicated amount 
of helicase. The concentration of the 71-bp partial duplex substrate 
in the reaction mixture was -2 p~ (DNA phosphate). The concen- 
tration of the 245-bp substrate in the assay was 188 nM (DNA 
phosphate). Unless otherwise specified, all DNA-binding compounds 
were added to the helicase reaction prior to the addition of the 
enzyme. Reactions were incubated at 37 "C for 10 min and terminated 
by the addition of 10 p1 of 50 mM EDTA, 40%  glycerol, 0.5% sodium 
dodecyl sulfate, 0.1% bromphenol blue, and 0.1% xylene cyano]. The 
products of the helicase reaction using the 71-bp partial duplex 
substrate were resolved on an 8% nondenaturing polyacrylamide gel. 
Electrophoresis was at 5-15 V/cm for 14 h. The products of the 
helicase reaction using the 245-bp fully duplex helicase substrate were 
separated on a 5% nondenaturing gel containing 0.1% sodium dodecyl 
sulfate. Electrophoresis was at 9 V/cm for 14  h. Polyacrylamide gels 
were analyzed by film autoradiography or by slicing the gel into 1-cm 
sections and counting  in  a liquid scintillation counter. 
ATPase Assays-The hydrolysis of ATP catalyzed by helicase I1 
was assayed by measuring the formation of [3H]ADP from [3H]ATP 
as described (27). The reaction conditions were identical to those 
described for the helicase reaction, except that [3H]ATP (3.0 cpm/ 
pmol) was substituted for ATP  at a  concentration of 4 mM. 
RESULTS 
Inhibition of Helicase 11 by DNA-binding Compounds-The 
effect of various DNA-binding compounds on the helicase 
reaction catalyzed by E. coli DNA helicase I1 was measured 
using the 71-bp partial duplex substrate  (Table  I). Initially, 
each compound was assayed for inhibitory activity at final 
concentrations of 1,10,  and 100 pM in an effort to obtain an 
approximate Ki.  The minor groove binders H33258, dista- 
mycin, and Netropsin did not  inhibit helicase I1 at concentra- 
tions up to 100 p ~ .  DAPI and Berenil were the only minor 
groove-binding drugs used in  this study that were active at 10 
and 100 p ~ ,  respectively. Novobiocin, camptothecin, and VM- 
26, all effective topoisomerase inhibitors, failed to inhibit 
helicase I1 at all the concentrations  tested. 
By far  the most interesting ligands tested were the DNA 
intercalators. Amiloride, genistein, acridine, actinomycin D, 
and m-AMSA  were not effective inhibitors, displaying appar- 
TABLE I 
Effects of DNA-binding compounds on the unwinding activity of 
helicase II  
Helicase reactions were as described under "Experimental Proce- 
dures" using 40 ng  of helicase 11. Preincubations of compounds with 
the helicase substrate were carried out for 5 min at room temperature 
prior to addition of helicase 11. In control reactions, helicase I1 
catalyzed the displacement of -50% of the 71-nucleotide fragment. 
The  data represent the average of at least  three independent deter- 
minations. 
Compound Apparent K; 
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ent Ki values >lo0 p ~ .  Ellipticine and ethidium inhibited 
helicase I1 with an  apparent Ki of -10 p ~ ,  whereas dauno- 
mycin inhibited helicase I1 with an  apparent Ki of -4 p ~ .  Of 
note, however, mitoxantrone and nogalamycin inhibited the 
unwinding activity of helicase I1 with an  apparent Ki of 1 p~ 
or less. 
Mechanism of Inhibition-In an effort to determine the 
mechanism by which mitoxantrone  inhibited the helicase I1 
unwinding reaction, the effects of mitoxantrone  on both  the 
unwinding and ATPase  activities of helicase I1 were measured 
simultaneously using the 71-bp partial duplex substrate (Fig. 
1). The  apparent Ki value for inhibition of both  the unwinding 
reaction and  the ATPase  activity of helicase I1 by mitoxan- 
trone was 0.9 p ~ .  
Inhibition of both the ATPase and unwinding activities of 
helicase I1 by mitoxantrone using the 71-bp partial duplex 
substrate may be explained by one of several mechanisms. 
First, mitoxantrone may inhibit  both  activities by binding to 
ssDNA and disrupting the unidirectional translocation of 
helicase I1 along ssDNA. This would prevent helicase I1 from 
reaching the duplex region and  thus would inhibit the  un- 
winding reaction indirectly. Second, mitoxantrone may in- 
hibit helicase I1  by intercalating into  the duplex DNA present 
on  the substrate. Duplex DNA in  this case includes the 71-bp 
region used to measure unwinding activity and duplex regions 
of  DNA present as hairpins  in M13mp7 ssDNA (30). Evidence 
for binding of mitoxantrone to  both ssDNA and dsDNA has 
been well documented (28,29). Third, mitoxantrone may bind 
directly to helicase I1 and  inhibit  both activities by preventing 
an interaction between helicase I1 and  the DNA substrate. 
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FIG. 1. Effect of mitoxantrone on helicase and ATPase ac- 
tivities of helicase I1 utilizing 71-bp partial duplex DNA as 
substrate. The 71-bp partial duplex substrate was preincubated with 
increasing concentrations of mitoxantrone for 5 min at  room temper- 
ature in helicase I1 reaction mixtures containing 4 mM ["HJrATP. 
Helicase I1 (32 ng) was added, and  the reactions were incubated at 
37 "C for 10 min. Reaction mixtures (20 pl) were analyzed for the 
production of ['HIrADP (5 pl)  and  the displacement of the 71-bp 
DNA fragment (15 pl). A,  typical autoradiograph of a helicase assay. 
Lane I ,  heat-denatured control; lane 2, no enzyme control; lanes 3- 
11, mitoxantrone concentrations as indicated. B, data for both heli- 
case (0) and ATPase (0) activities shown as  percent  control activity 
as a function of the micromolar concentration of mitoxantrone. In 
control reactions, helicase I1 catalyzed the displacement of -50% of 
the 71-nucleotide fragment and hydrolyzed -5.2 nmol of ATP (out 
of 80 nmol present in the reaction). All data points  are the average 
of a t  least three independent determinations. 
To determine  whether  mitoxantrone  inhibits the interac- 
tion between helicase I1 and ssDNA, the effect of mitoxan- 
trone on the DNA-dependent ATPase reaction was tested 
using  either  poly(dT) or M13mp7 ssDNA (without the 71-bp 
annealed fragment) as effectors of the ATPase reaction. 
Poly(dT) DNA lacks the secondary structure  that exists in 
the M13mp7 ssDNA, making  intercalation into duplex regions 
unlikely. As shown in Fig. 2, mitoxantrone did not effectively 
inhibit  the ATPase  activity of helicase I1 at concentrations 
up  to 2.5 p~ when poly(dT) DNA  was the ssDNA effector. 
(The inhibition of ATPase  activity between 2.5 and 4.0 pM 
mitoxantrone may result from a condensation of poly(dT) 
DNA caused by high concentrations of mitoxantrone as de- 
scribed by Kapuscinski and Darzynkiewicz (28) (see "Discus- 
sion").) In  contrast,  the results  obtained using M13 ssDNA 
without the 71-bp annealed fragment compared favorably 
with those  obtained with the 71-bp helicase substrate. The 
apparent Ki for inhibition of this ATPase reaction was 2.0 
p ~ .  Thus,  the  apparent Ki for mitoxantrone as  an inhibitor 
of the ATPase reaction using M13 ssDNA was  close to  that 
observed for the 71-bp partial duplex helicase substrate.  These 
results strongly suggest that mitoxantrone, when present at  
low concentrations, does not inhibit the ATPase reaction 
catalyzed by helicase I1 when ssDNA is provided as the 
effector of the reaction. These  results also suggest that mitox- 
antrone does not inhibit the ATPase activity by binding 
directly to helicase I1 since there was little effect on ATP 
hydrolysis, at  low mitoxantrone  concentrations, when 
poly(dT) was used as  the DNA effector. 
In light of the results  presented above, it was necessary to 
determine  what effect mitoxantrone  had  on the helicase re- 
action when the drug was preincubated with helicase 11. 
Helicase I1 was preincubated with 2 p~ mitoxantrone  under 
normal reaction conditions in the presence or absence of ATP. 
After preincubation, the drug/helicase I1 mixture was diluted 
to a final concentration of 0.05 or 0.1 p~ mitoxantrone, and 
helicase activity was measured. Controls were treated the 
same way without  mitoxantrone present. The results of this 
study are presented in Table 11. There was little or no effect 
of preincubating helicase I1 with mitoxantrone. The results 
I I I I I 
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FIG. 2. Mitoxantrone inhibits ATPase activity of helicase 
I1 on M13 ssDNA, but not on poly(dT) DNA. Either M13  ssDNA 
or poly(dT) ssDNA (2 p~ nucleotide) was preincubated with increas- 
ing concentrations of mitoxantrone at  room temperature for 5 min in 
helicase I1 reaction mixtures containing 4 mM [3H]rATP. Helicase 11 
(32 ng) was added, and  the reactions were incubated for 10 min at 
37 "C. Reaction mixtures (20 pl) were analyzed by measuring the 
production of [3H]rADP in  a 5-pl aliquot. Data for M13mp7  ssDNA 
(0) and poly(dT) ssDNA (0) are shown as  percent control activity 
as  a function of the micromolar concentration of mitoxantrone. In 
control reactions, helicase I1 catalyzed the hydrolysis of -28 nmol of 
ATP (out of 80 nmol present in the reaction). All data points 
represent the average of a t  least three independent determinations. 
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TABLE I1
Preincubations of helicase I1 and mitoxantrone 
Preincubation  mixtures (10 pl) containing helicase I1 (320 pg) and 
2 p M  mitoxantrone were incubated in helicase I1 reaction mixtures 
with or without 4 mM rATP for 5 min a t  room temperature.  After 
preincubation,  the  mixture was diluted to reduce the  mitoxantrone 
concentration. Helicase activity was measured  using  the 71-bp partial 
duplex DNA substrate.  Controls were treated  in  the  same way without 
the addition of mitoxantrone. The final  concentrations of mitoxan- 
trone  in  the helicase  reaction containing  16  and  32  ng of helicase I1 
were 0.05 and 0.1 p ~ ,  respectively. Helicase reactions (20 pl) were 
performed as described under  "Experimental Procedures." In  control 
reactions, helicase I1 catalyzed  the  displacement of 35% (16  ng)  and 
55% (32  ng) of the 71-nucleotide fragment. 
Displacement 
% control activity 
No  rATP 
16  ng helicase I1 93 
32 ng helicase I1 100 
16  ng helicase I1 a4 
32  ng helicase I1 98 
4 mM rATP 
from  the  preincubation  performed  in  the  presence of rATP 
were virtually  identical to  those  without  rATP.  These  results 
support  the  hypothesis  that  mitoxantrone  does  not  interact 
directly  with helicase 11, but  interacts  with  the  DNA to inhibit 
helicase 11. These results, together with those presented in 
Fig. 2, suggest that helicase I1 is  inhibited  when  mitoxantrone 
intercalates  into dsDNA. 
To  directly  test  the effect of mitoxantrone  on  the  unwinding 
reaction  in  the  absence of any  ssDNA, we took advantage of 
the  fact  that helicase I1 will unwind blunt-ended, fully du- 
plexed DNA fragments (20). Unwinding of a 245-bp fully 
duplex DNA fragment  was effectively inhibited by mitoxan- 
trone with an apparent Ki of 0.9 p~ (Fig. 3). This K, is 
identical  to  the  apparent Ki measured  using  the 71-bp partial 
duplex  substrate.  These  results clearly  suggest that  the  inhi- 
bition observed  for both  substrates  is likely accomplished by 
the  same  mechanism of inhibition. Additionally, the effect of 
mitoxantrone  on  the  ATPase  reaction  catalyzed by  helicase 
I1 was measured  using the 245-bp blunt-ended  fragment (Fig. 
3). The  apparent K,  for  mitoxantrone  in  this  reaction was 1.4 
p ~ .  Again, this Ki is almost identical to the apparent Ki 
measured  using  the 71-bp partial  duplex  substrate. If, how- 
ever,  the 245-bp DNA  substrate was denatured  prior to the 
addition of mitoxantrone  and helicase 11, mitoxantrone  inhib- 
ited  the  ATPase  reaction less well, with  an  apparent K, of 6 
p ~ .  These  data suggest that  the  mechanism of inhibition of 
helicase I1 is  through  the  intercalation of mitoxantrone  into 
the  dsDNA  substrate.  The  decrease  in  unwinding  activity  is 
the direct  result of the  inability of helicase I1 to move through 
duplex regions when mitoxantrone is bound. Most of the 
decrease  in  ATPase  activity  observed  when  mitoxantrone  is 
complexed with  the  native  substrate  occurs  for  the following 
reasons.  First,  the hydrolysis of ATP is  required to unwind 
the  duplex  DNA. Second,  the  ssDNA  generated  as  result of 
the unwinding reaction can serve as  an effector DNA for 
further hydrolysis of ATP by helicase 11. 
Inhibition of Other DNA Helicases by DNA-binding Com- 
pounds-To  determine if the  inhibition of helicase I1 by DNA 
intercalators was unique to  this enzyme, the effect of mitox- 
antrone, nogalamycin, m-AMSA, and  H33258  on  the helicase 
activity of E.  coli Rep protein and helicases I and IV was 
determined utilizing the 71-bp partial duplex helicase sub- 
strate  (Table 111). These four drugs were selected  to  represent 
both  potent  inhibitors  (mitoxantrone  and  nogalamycin)  and 
inhibitors  that showed no effect on helicase I1 a t  concentra- 
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FIG. 3. Mitoxantrone  inhibits helicase I1 when  245-bp 
blunt-ended duplex DNA is utilized as substrate. The 245-hp 
blunt-ended  duplex DNA  was preincuhated  with  increasing  concen- 
trations of mitoxantrone in helicase 11 reaction  mixtures  containing 
4 mM ['HIrATP for 5 min a t  room temperature.  Helicase I1  (I60 ng) 
was added, and the reactions were incubated for 10 min a t  37 "C. 
Reaction  mixtures (20 pl) were analyzed for the  production of ['HI 
rADP  using a 5-pl aliquot  and  unwinding of the  duplex DNA using a 
15-pl aliquot. A, typical autoradiograph of a  helicase assay. Lane 1, 
heat-denatured  control; lane 2. no  enzyme  control; lanes 3-10, mitox- 
antrone concentrations as indicated. R, data for both he1ica.w (0) 
and ATPase (0) activities shown as percent control activity as a 
function of the micromolar concentration of mitoxantrone. In a 
separate  reaction,  the  245-hp  DNA  substrate  was  heat-denatured a t  
95 'C for 5 min  prior to preincubation with mitoxantrone. ATPa.se 
reactions were carried out as described  above. Data for ATPase 
activity (A) utilizing  the  heat-denatured  substrate  are  presented  as 
described above. In control reactions, helicase I1  catalyzed the un- 
winding of -50% of the 245-bp substrate  and hydrolyzed -12 nmol 
of ATP (out of 80 nmol present in the reaction). All data pointn 
represent  the  average of a t  least  three  independent  determinations. 
TABLE I l l  
Inhibition of Rep protein and helicages I and IV by 
DNA-binding 1iRand.q 
Helicase reactions were as described  under  "Experimental  Proce- 
dures"  using helicase I (14 ng),  Rep  protein  (75  ng). or helicase IV (4  
ng)  plus 2 mM rATP  and  the  71-hp  partial duplex  helicase substrate. 
Comparisons were made to zero  ligand controls, which catalyzed the 
displacement of -50% of the  71-nucleotide  fragment.  Preincuhations 
of DNA-binding compounds with the helicase substrate were for 5 
min a t  room temperature.  Reactions were initiated with  helicase and 
incubated a t  37 "C for 10 min. The  data  represent  the average of at  
least  three indeDendent determinations. 
Compound 
Apparent K ,  
He1ica.w I Rep protein Helicaw I\' 
PM 
Nogalamycin <IO < I  <I 
Mitoxantrone <IO <IO <IO 
m-AMSA >IO >10 >I0  
H33258 >10 >10 < I  
tions up to 10 p~ (m-AMSA and H33258). Nogalamycin 
inhibited all three helicases dramatically. Helicase IV waR 
inhibited  completely a t  1 p~ nogalamycin, whereas Rep pro- 
tein  and helicase I were inhibited to G O %  of control activity 
at 1 pM and  10 pM nogalamycin, respectively. Mitoxantrone 
inhibited all three helicases with apparent K, values of be- 
tween l and 10 p ~ .  In  contrast, m-AMSA  did not  inhibit Rep 
protein  or helicase I or IV a t  10 PM. Likewise, H3.7258 did not 
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inhibit helicase I or Rep protein significantly a t  10 pM. 
However, helicase IV was inhibited by H33258 at 1 pM to 
<50% of control activity. These data suggest that each enzyme 
has  its own spectrum of sensitivities to DNA-binding ligands 
and  that  the inhibition of helicase I1  by these compounds is 
not unique. 
DISCUSSION 
The duplex DNA unwinding reaction and  the associated 
ATPase reaction catalyzed by helicase I1 can be inhibited by 
several ligands that bind DNA. This inhibition has been 
shown to be highly specific with respect to  the drug used. The 
topoisomerase inhibitors novobiocin, VM-26, and  camptothe- 
cin, which  do not  bind DNA directly, showed no effect on  the 
helicase reaction. In addition, drugs that bind to  the minor 
groove in duplex DNA such as H33258, distamycin, Netrop- 
sin, DAPI, and Berenil also fail to inhibit the helicase I1 
unwinding reaction at  low concentrations.  These ligands re- 
quire  3  or more consecutive AT  bp for binding (5, 31,  32,  34, 
35), and  there  are four such  sites  in the 71-bp partial duplex 
substrate (36). Thus, failure of these drugs to bind the sub- 
strate is not  a likely explanation for their  inability to inhibit 
the unwinding reaction. It is interesting to note that DAPI, 
which falls into this broad class of drug, does inhibit the 
unwinding reaction slightly a t  a  concentration of 10 pM. Since 
DAPI  has been shown to intercalate at GC or mixed sequences 
(6), the inhibition of helicase I1 caused by DAPI may be due 
to intercalation of the compound into  the DNA substrate. In 
general, ligands that bound dsDNA by intercalation were the 
most effective inhibitors of the helicase I1 unwinding reaction. 
These DNA-binding compounds varied both  in  their  inhibi- 
tion of the helicase I1 unwinding reaction and  in  their  struc- 
ture,  as discussed below. The two most potent  inhibitors of 
the unwinding reaction were nogalamycin and mitoxantrone. 
Analysis of the effect of mitoxantrone on both the unwind- 
ing reaction and  the ATPase reaction catalyzed by helicase 
11, using various DNA substrates, suggests that  the mecha- 
nism by which the drug inhibits the reaction is through 
intercalation  into the duplex DNA substrate. This presumably 
provides a physical block to continued  translocation by the 
helicase, causing the unwinding reaction to be inhibited. Ini- 
tial experiments demonstrated  inhibition of both  the DNA- 
dependent  ATPase reaction and  the helicase reaction on the 
71-bp partial duplex substrate. The  apparent Ki values for 
inhibition of both  these reactions were essentially identical. 
The substrate  contains -7000 nucleotides of ssDNA in  addi- 
tion  to  the 71-bp duplex region. Inhibition of both the ATPase 
and helicase activities to the same extent a t  all  drug concen- 
trations tested suggested three possibilities. First,  mitoxan- 
trone could inhibit helicase I1 by binding directly to the 
enzyme and preventing its association with the DNA sub- 
strate. Second, mitoxantrone could bind to ssDNA and  inhibit 
helicase I1  by preventing ATP hydrolysis-fueled translocation 
to  the duplex region. Third, intercalation of mitoxantrone 
into &DNA regions on the DNA substrate could disrupt  both 
translocation to the duplex region and unwinding of the 
duplex region. With regard to  this possibility, it  is  important 
to note that M13 ssDNA contains several regions capable of 
forming hairpin  structures (30). Mitoxantrone can presum- 
ably  intercalate  into  these regions of dsDNA. 
TO distinguish among these possibilities, the effect of mi- 
toxantrone on the DNA-dependent ATPase  activity of heli- 
case I1 was measured using two different DNA effectors of 
the ATPase reaction: either M13 ssDNA, which contains 
secondary structure, or poly(dT), which lacks secondary struc- 
ture.  Mitoxantrone effectively inhibited the ATPase reaction 
using M13 ssDNA with an apparent Ki of 2 p ~ .  In  contrast, 
the drug had little effect on the ATPase reaction when 
poly(dT) was the DNA effector at mitoxantrone  concentra- 
tions <2.5 pM. However, as  the mitoxantrone  concentration 
was increased to 4 p ~ ,  there was a decrease in the ATP 
hydrolysis reaction rate to -60% of control activity. This 
inhibition of activity was most likely due to condensation of 
poly(dT) by mitoxantrone, which has been reported to occur 
at a  concentration of  -2-3 p~ (28). Nevertheless, the ATPase 
activity was not completely inhibited by mitoxantrone, per- 
haps due to  the presence of short DNA fragments that are 
not removed in  the condensation reaction. Inhibition of the 
ATPase reaction in  the presence of M13 ssDNA was not  a 
result of condensation of the DNA by mitoxantrone since the 
critical concentration of drug required for condensation of 
this DNA is -6.6 p ~ ,  which is well above the Ki for inhibition. 
This suggests that  the predominant mechanism of inhibition 
at low drug concentrations is through  intercalation  into the 
secondary structure  present  in M13  ssDNA. It is likely that 
helicase I1 either dissociates from the DNA  molecule or be- 
comes trapped within duplex regions as it encounters drug 
intercalated in dsDNA. 
It is also unlikely that mitoxantrone binds directly to heli- 
case I1 to inhibit the activities of the enzyme. This is evi- 
denced by the fact that inhibition of the ATPase reaction at 
low drug  concentrations  is DNA structure-dependent.  In  ad- 
dition,  control  experiments  in which helicase I1  was incubated 
with inhibitory  concentrations of mitoxantrone prior to dilu- 
tion  into an unwinding reaction demonstrated no inhibition 
of the enzyme’s activities. Thus, we conclude that mitoxan- 
trone and presumably other DNA intercalators inhibit the 
unwinding and ATPase reactions catalyzed by helicase I1 
through the generation of a mitoxantrone-dsDNA complex 
that impedes movement of the enzyme. 
To support the conclusion that specific DNA intercalators 
inhibit helicase I1  by intercalation  into dsDNA regions, sev- 
eral  experiments were performed using a 245-bp blunt-ended 
duplex DNA substrate.  These experiments take advantage of 
the fact that helicase I1 is able to unwind a fully duplex DNA 
molecule  by initiation of the unwinding reaction at  the ends 
of the  substrate (20). This  substrate provides the added ben- 
efit of having no ssDNA to which the drug can  bind by some 
other type of interaction. As expected, mitoxantrone inhibited 
both the unwinding reaction and  the ATPase reaction cata- 
lyzed  by helicase I1 when measured using the 245-bp duplex 
substrate. The  apparent Ki for inhibition of the unwinding 
reaction was 0.9 pM, in excellent agreement with that observed 
using the 71-bp partial duplex substrate.  These  results uggest 
that  the mechanism of inhibition was the same in each case, 
despite the considerable differences in  the two substrates. The 
apparent Ki for inhibition of the ATPase reaction was  1.4 p ~ .  
When the duplex substrate was denatured prior to  the addi- 
tion of helicase 11, the  apparent Ki for inhibition was 6.0 p~ 
mitoxantrone.  Thus, the effect of mitoxantrone on the ATP- 
ase reaction was markedly reduced when the DNA effector 
was  ssDNA. These  results  further  support the conclusion that 
the inhibition of the helicase reaction is the result of an 
interaction between dsDNA and  mitoxantrone. Moreover, the 
apparent Ki for inhibition of the helicase reaction is far below 
the critical concentration of mitoxantrone required for con- 
densation of dsDNA (14.7 I.LM for calf thymus DNA) (28). 
Thus,  it is apparent  that  the inhibition of helicase activity is 
due to intercalation of the drug into  the duplex DNA substrate 
and  that  the inhibition of ATP hydrolysis reflects the coupling 
of ATP hydrolysis to unwinding of duplex regions. We con- 
clude that intercalation of mitoxantrone  into dsDNA gener- 
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ates a complex that impedes the progress of helicase 11, 
resulting in either dissociation of helicase I1 from the sub- 
strate or physical trapping of the enzyme on the DNA.  We 
cannot distinguish between these two possibilities at this time. 
The DNA intercalators used in  this  study varied both  in 
structure  and efficiency of inhibition of helicase 11. To begin 
defining properties of the intercalators that  are  important for 
the inhibition of helicase 11, we examined the relationship of 
unwinding angle and DNA binding affinity to inhibitory 
activity  (Table IV). Neither  parameter correlates with inhi- 
bition of helicase I1 activity. For example, nogalamycin and 
mitoxantrone, the two most potent helicase I1 inhibitors, have 
unwinding angles of 18" and 23", respectively. m-AMSA, 
which does not  inhibit helicase 11, has  a measured unwinding 
angle of 21". 
Acridine, genistein, and amiloride are simple DNA inter- 
calators without functional groups positioned in either groove 
of dsDNA. None of these compounds inhibited helicase 11, 
suggesting that simple intercalation is not sufficient for in- 
hibition. Both m-AMSA and actinomycin D also failed to 
inhibit helicase 11. Structural  studies of actinomycin D-DNA 
complexes (38) demonstrate selective binding to GC sites, 
with the two large cyclic peptides positioned in the minor 
groove of &DNA (39). m-AMSA intercalates  into DNA, with 
its acridine chromophore and  the noncoplanar 9-anilino  ring 
positioned in  the minor groove (40). Since neither compound 
inhibited helicase 11, intercalation coupled with a  functional- 
ity placed in the minor groove may also not be adequate for 
inhibition. The results obtained with ethidium and ellipticine 
are more difficult to interpret. The ethidium-DNA complex 
has been well studied by x-ray diffraction techniques  (41,42). 
These studies suggest that  the drug's ethyl  and phenyl func- 
tionalities  are positioned in  the minor groove of dsDNA. The 
weak inhibition observed with ethidium may result from 
electrostatic binding to  the phosphodiester backbone of 
ssDNA (43). The significance of the ellipticine inhibition 
cannot be evaluated until  additional work is carried out  to 
define the ellipticine-DNA complex. 
Daunomycin, nogalamycin, and  mitoxantrone (Fig. 4) were 
the most potent  inhibitors of the helicase I1 unwinding reac- 
tion;  and  they were the only intercalators  tested that position 
functionalities in the major groove when bound to dsDNA. 
The daunomycin-DNA complex has been  well described (45, 
46); ring D of the aglycon chromophore resides in  the major 
groove when this ligand intercalates into dsDNA. Nogala- 
mycin, an anthracycline antibiotic, intercalates  into dsDNA 
and places the nogalose sugar in  the minor groove; the charged 
dimethylamino group and  the hydroxyl functionalities of the 
bicyclic sugar are positioned in the major groove (47-49). 
High-field 'NMR studies of the mitoxantrone-DNA interac- 
tion suggest that  the intercalation chromophore is positioned 
perpendicular to the base pairs, with the two side chains 
residing in the major groove (50). Thus, nogalamycin and 
mitoxantrone, the most potent  inhibitors, position a positively 
TABLE IV 
Unwinding angles and binding constants for DNA intercalation 
Intercalator Unwinding angle & Ref. 
f iM 
Amiloride 5.9" 51 
Ethidium 26" 1 2,  43 
Actinomycin D 26" 0.2 2 
m-AMSA 21" 1, 10 2, 33,  37,  40 
Ellipticine 17" or 9" 6.6  2,  44
Daunomycin 11" 0.4  2,  46
Nogalamycin 18" 2.0  2, 48 
Mitoxantrone 26.5',  17.5",  23" 0.2 29,  50, 53, 54 
" ' O d  
M e 0  OM* 
FIG. 4. Chemical structures of mitoxantrone ( A ) ,  nogala- 
mycin (B) ,  and daunamycin (C). 
charged amino group and two hydroxyl groups in  the major 
groove. 
Taken together, the  data suggest the possibility that inhib- 
itory intercalators must place a functionality in the major 
groove when bound to DNA or that  the binding of a ligand in 
the major groove, in the absence of intercalation, may be 
sufficient for inhibition of helicase 11. The  data do not dis- 
criminate between these two possibilities. Although there  are 
no small DNA-binding ligands that interact solely with the 
major groove of DNA, construction of DNA triplex substrates 
may provide further insight into  this problem. Until  further 
analysis  is  carried out, the exact requirements for inhibition 
of helicase activity  must be considered speculative. 
The ligands that were effective inhibitors of DNA helicase 
I1 exhibit both  antitumor  and mutagenic properties (for re- 
views, see Refs. 1 and 2). In addition, it has been demonstrated 
that inhibition of helicase activity by DNA-binding com- 
pounds is not  restricted to helicase 11. Three additional heli- 
cases, Rep protein  and helicases I  and IV,  were also inhibited 
by a spectrum of the compounds tested  in  this study (Table 
111). In fact, a range of sensitivities was obtained that de- 
pended on both the compound and  the helicase tested.  These 
results may  be important for understanding  both the mecha- 
nism by which duplex DNA is unwound by a helicase and the 
mechanism by which these compounds inhibit cellular func- 
tion. Thus, it may be possible that some of the cytotoxic 
properties exhibited by these drugs are due to  an inhibition 
of specific helicase reactions in the cell, as helicases are known 
to be  involved in all aspects of DNA metabolism. For example, 
although m-AMSA and mitoxantrone show a similar capacity 
to induce cleavable complexes in cellular DNA, mitoxantrone 
is far more cytotoxic than m-AMSA to human cells (52). 
Additional biochemical and genetic analysis will  be required 
to test  these ideas. 
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